Advised on sale of biotechnology manufacturing company

Subscribe To Transaction News

Advised on sale of biotechnology manufacturing company

Subscribe To Transaction News

John and his team advised Sorrento Therapeutics on its $35 million public offering. Our services included advising the company through a reverse stock split to meet the Nasdaq’s share-price requirement for listing on the Capital Market, raising capital, and coordinating with the exchange to ensure completion of the uplisting.

Note: This work was performed prior to joining Stout.